MiddleBrook Pharmaceuticals Reports First Quarter 20...(from the exercise of stock options and w...),Health

million from the sale of fixed assets, and $0.3 million for working

capital changes and other items; offset by $6.7 million of operating

losses in the quarter.

-- The Balance Sheet at March 31, 2008 reflected $18.0 million of

unrestricted cash, cash equivalents and marketable securities, compared

to $2.0 million as of year-end 2007.

FINANCIAL GUIDANCE

MiddleBrook's financial guidance remains unchanged from prior forecasts. Total revenue for 2008 is expected to be approximately $10 million to $12 million, resulting from Keflex product sales and assuming no generic competition to Keflex 750 mg capsules occurs during the year. Total cash used in operating activities and capital expenditures in 2008 is estimated to be between $17 and $19 million. These forecasts also assume no financial impact from the Company's recently approved MOXATAG product, pending the outcome of its ongoing strategic process.

Assuming the Company's expectations for continued sales of its Keflex 750 mg product and anticipated level of R&D spending and other obligations, MiddleBrook believes that its current funds, together with expected Keflex product sales, will be sufficient to support its currently planned operations into 2009. These 2008 estimates are forward-looking statements that involve risks and uncertainties, and actual results could vary materially.

ABOUT MIDDLEBROOK PHARMACEUTICALS:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The C
'/>"/>